-
-
-
-
-
-
-
ADAR1 urges Keros board to discuss strategy after meeting requests declined
-
-
-
-
-
-
-
Keros Therapeutics (KROS) Return of $375M in Excess Capital to Stockholders
-
-
-
-
-
-
-
Keros Therapeutics (KROS) call put ratio 1 call to 1.1 puts as share price up 20%
-
-
-
-
-
-
-
Keros Therapeutics (KROS) Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
-
-
-
-
-
-
-
Keros Therapeutics (KROS) PT Lowered to $43 at Truist Securities
-
-
-
-
-
-
-
Keros Therapeutics (KROS) PT Raised to $102 at Guggenheim
-
-
-
-
-
-
-
Keros Therapeutics (KROS) Appoints Yung H. Chyung as Chief Medical Officer
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

